Biosign Certified for Non-invasive Blood Glucose Monitoring

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, February 11 - Biosign Technologies Inc. (CNSX: BIO) ("Biosign" or the "Company") today
announced it has been assessed and certified as meeting the requirements of
ISO 9001:2008, ISO 13485-2003, and Directive 93/42/EEC ("CE Mark") for
automated wrist blood pressure and blood glucose monitors with computer
controls. The certificates allow Biosign to add non-invasive blood glucose
monitoring to its offerings in the European Union and other regions that
recognize these certifications.

Practically, UFIT(R) TEN-20 is a blood pressure monitor that also reads
blood glucose. There is no additional hardware. Measurements are completely
non-invasive, with results verifiable for accuracy and relevance.

"Researchers have attempted for years to find a solution that can
eliminate the need for pricking the skin and drawing blood to measure glucose
levels", said Peter Tassiopoulos, Biosign's Chief Operating Officer. "UFIT(R)
TEN-20 solves this issue and, more importantly, it keeps an audit trail of
every measurement taken for future reference."

The company is scaling resources for support and manufacturing to prepare
for the anticipated demand by the market for the newly certified capability
of the UFIT(R) system. "We can now proceed confidently on executing our
ambitious plans for 2010." said Radu Leca, President and CEO of Biosign.

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent
systems for noninvasive monitoring of common health risks associated with
blood pressure, glucose, and medication. The core technology combines
measurement, analysis, and rapid knowledge formation to support health
monitoring across global markets. The UFIT(R) medical device technology
powers quality data collection and analytics for clinical diagnostics,
self-care, wellness, disease state evaluation & management, and remote
patient monitoring. For more information on Biosign please visit
www.biosign.com

The CNSX has neither approved nor disapproved the contents of this press
release.

For further information: Radu Leca, President & CEO, Biosign Technologies
Inc., +1-416-218-9800 ext. 234, ceo@biosign.com

For further information: Radu Leca, President & CEO, Biosign Technologies Inc., +1-416-218-9800 ext. 234, ceo at biosign.com